Sprache auswählen
C-MET
C-MET Molekülinformation
| Englischer Name | Hepatocyte growth factor receptor | Anzahl der inverkehr gebrachten Arzneimittel | 13 |
| Anzahl der klinischen Arzneimittel | 72 | Target-Alias | EC 2.7.10，EC:2.7.10.1，HGF receptor，HGF/SF receptor，Hepatocyte growth factor receptor，Tyrosine-protein kinase Met，MET，SF receptor，Scatter factor receptor，MET Proto-Oncogene， Receptor Tyrosine Kinase，Proto-Oncogene C-Met，Met Proto-Oncogene，EC 2.7.10.1，DFNB97，AUTS9，RCCP2，C-Met，HGFR，Proto-Oncogene Proteins c-met |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Hepatocyte growth factor receptor |
| Target-Alias | EC 2.7.10，EC:2.7.10.1，HGF receptor，HGF/SF receptor，Hepatocyte growth factor receptor，Tyrosine-protein kinase Met，MET，SF receptor，Scatter factor receptor，MET Proto-Oncogene， Receptor Tyrosine Kinase，Proto-Oncogene C-Met，Met Proto-Oncogene，EC 2.7.10.1，DFNB97，AUTS9，RCCP2，C-Met，HGFR，Proto-Oncogene Proteins c-met |
| Anzahl der inverkehr gebrachten Arzneimittel | 13 |
| Anzahl der klinischen Arzneimittel | 72 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
C-MET Produktliste
- Attribut
Antibody (1)
- Produktbibliothek
Online (1)
- Spezies
Rabbit (1)
- Etikett
- (1)
- Marker
Unconjugated (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
HGS-S303 |  Rabbit | - | Recombinant Monoclonal Anti-C-MET Antibody, Rabbit (1A1) |  In den Warenkorb legen |
Gesamtmenge1
- 1
C-MET Molekülalias
C-MET
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Recombinant plasmid-hepatocyte growth factor | Pudk-HGF | Phase 3 Clinical | Academy Of Military Medical Sciences, Wuhan Optical Valley Humanwell Biological Pharmaceutical Co Ltd | Ischemia; Peripheral Arterial Disease | Details |
| Fosgonimeton | NDX-1017; ATH-1017; ATH 1017 | Phase 3 Clinical | M3 Biotechnology | Alzheimer Disease; Dementia; Lewy Body Disease; Parkinson Disease | Details |
| Sitravatinib | MG-516; MG-91516; MGCD-516; IND-155305; MGCD-0516 | Phase 3 Clinical | Mirati Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Hepatic Insufficiency; Kidney Neoplasms; Liposarcoma; Lung Diseases; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Oral Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Ureteral Neoplasms; Uterine Cervical Neoplasms; Uveal melanoma | Details |
| HS-20117 | HS-20117; PM1080; PM-1080 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details | |
| Telisotuzumab adizutecan | ABBV-400 | Phase 3 Clinical | Abbvie Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| ASKC-202 | ASKC202 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| AL-2846 | AL-2846 | Phase 3 Clinical | Advenchen Laboratories Nanjing Ltd | Bone metastases; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ganglioglioma; Liver Neoplasms; Lung Neoplasms; Medullary thyroid cancer (MTC); Neoplasms; Neurilemmoma; Neurofibroma; Neurofibromatoses; Neurofibromatosis 1; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms | Details |
| Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Intestinal Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Do-1 | OMO-1; JNJ-38877618; Do-1 | Phase 2 Clinical | Johnson & Johnson | Lung Neoplasms; Neoplasms | Details |
| Pamvatamig | MCLA-129 | Phase 2 Clinical | Merus Nv | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| Vabametkib | KDDF-201603-08; ABN-401 | Phase 2 Clinical | Abion Inc | Neoplasms; Solid tumours | Details |
| VBC-101-F11 | VBC-101; VBC101F11; VBC101 | Phase 2 Clinical | Shanghai Orange Sail Pharmaceutical Co Ltd | Solid tumours | Details |
| Bafisontamab | FIT-013a; EMB-01 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Digestive System Neoplasms; Gastrointestinal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Stomach Neoplasms | Details |
| GB-263 | GB-263; GB-263T | Phase 2 Clinical | Genor Biopharma Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| MHB-042-C | MHB042C; MHB-042-C | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Neoplasms; Solid tumours | Details |
| Elzovantinib | TPX-0022 | Phase 2 Clinical | Turning Point Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours; Stomach Neoplasms | Details |
| TQB-6411 | TQB-6411; TQB6411 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Esophageal Neoplasms; Lung Neoplasms; Neoplasms | Details |
| SKB-571 | SKB-571; MK-2750; SKB571 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| CKD-703 | CKD-703 | Phase 2 Clinical | CKD Research Institute | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| KY-0301 | RB-601; KY-0301 | Phase 2 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours | Details |
| PRO-1286 | PRO-1286; GEN1286; GEN-1286 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Neoplasms; Solid tumours | Details |
| MDX-2001 | MDX2001; MDX-2001 | Phase 2 Clinical | ModeX Therapeutics Inc | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| PFL-002 | PFL-002; PFL-002/VERT-002; VERT-002 | Phase 2 Clinical | Vertical Bio AG | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Solid tumours | Details |
| TQB-2922 | TQB2922; TQB-2922 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Colorectal Neoplasms; Neoplasms | Details |
| ANS-014004 | ANS014004; ANS-014004; ANS-01; ANS01 | Phase 2 Clinical | Beijing Avistone Pharmaceuticals Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Solid tumours | Details |
| SHR-1826 | SHR-1826; SHR1826 | Phase 2 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| SHR-9839 | SHR-9839; SHR9839 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| Davutamig | REGN-5093 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
| CKD-702 | CKD-702 | Phase 2 Clinical | Chong Kun Dang Pharmaceutical Corp | Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms | Details |
| Recombinant adenovirus-hepatocyte growth factor(Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences) | Phase 2 Clinical | Beijing Haitai United Pharmaceutical Technology Development Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Myocardial Ischemia | Details | |
| RC-108 | RC-108; RC108 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Digestive System Neoplasms; Gastrointestinal Neoplasms; Solid tumours | Details | |
| Emibetuzumab | LA-480; LY-2875358 | Phase 2 Clinical | Eli Lilly And Company | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Gastroesophageal Junction Neoplasms; Lymphoma; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| CM-118 | CM-118 | Phase 1 Clinical | Xcovery | Carcinoma, Non-Small-Cell Lung; Neoplasms | Details |
| Kanitinib | CX-1003 | Phase 1 Clinical | Beijing Konruns Pharmaceutical Co Ltd, Guangzhou Yingsheng Bio Technology Co Ltd | Solid tumours | Details |
| BPI-9016 | BPI-9016; BPI-9016M | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| HLX-55 | HLX-55; KTN-0216 | Phase 1 Clinical | Kolltan Pharmaceuticals Inc | Solid tumours | Details |
| Pamufetinib | TAS-115 | Phase 1 Clinical | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | Neoplasms | Details |
| anti-c-Met CAR T-cell therapy (Abramson Cancer Center) | Phase 1 Clinical | Abramson Cancer Center of the University of Pennsylvania | Breast Neoplasms | Details | |
| Ad-NK4 gene therapy (Chiba Cancer Center Res Inst/Toho University/Tokyo Women’s Medical University Yachiyo Medical Center) | Phase 1 Clinical | Chiba Cancer Center | Mesothelioma | Details | |
| Boxitinib Hydrochloride | Phase 1 Clinical | Hec Pharm Co Ltd | Breast Neoplasms; Carcinoma, Renal Cell; Glioma; Lung Neoplasms; Stomach Neoplasms | Details | |
| BYON-3521 | BYON-3521 | Phase 1 Clinical | Byondis Bv | Neoplasms; Solid tumours | Details |
| ATH-1020 | ATH-1020 | Phase 1 Clinical | Athira Pharma Inc | Nerve Degeneration | Details |
| QLS-5316 | QLS5316; QLS-5316 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| SIM-0610 | SIM-0610; SIM0610 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasm Metastasis; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| HLX-48 | HLX-48 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details | |
| HS-20122 | HS-20122; HS20122 | Phase 1 Clinical | Shanghai Hansoh Biomedical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| ALK-202 | ALK-202; ALK202 | Phase 1 Clinical | Shanghai Allink Biotherapeutics Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Solid tumours | Details |
| NEP-018 | NEP-018; NEP018 | Phase 1 Clinical | Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd | Gastrointestinal Neoplasms | Details |
| 1-D-228 | 1D228; 1-D-228 | Phase 1 Clinical | Guangdong Lewwin Pharmaceutical Research Institute Co Ltd, Guangzhou Zhongkelian Pharmaceutical Research Co Ltd | Carcinoma, Non-Small-Cell Lung | Details |
| QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
| BG-T187 | BG-T187; BGT187 | Phase 1 Clinical | BeOne Medicines Ltd | Gastrointestinal Neoplasms; Lung Neoplasms; Solid tumours | Details |
| Do-2 | Do-2 | Phase 1 Clinical | DeuterOncology NV | Lung Neoplasms | Details |
| YL-211 | YL211; YL-211; RG-6648; RG6648 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | Details |
| FPI-2107 | [111In]-FPI-2107 | Phase 1 Clinical | Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| FPI-2053 | FPI-2053 | Phase 1 Clinical | Astrazeneca Plc, Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| DM-005 | DM005; YH013; DM-005 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| FPI-2068 | FPI-2068; [225Ac]-FPI-2068; AZD-2068 | Phase 1 Clinical | Astrazeneca Plc, Fusion Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| SPH-3348 | SPH-3348; SPH3348; I-020 | Phase 1 Clinical | Shanghai Pharmaceuticals Holding Co Ltd | Neoplasms; Solid tumours | Details |
| Tilatamig samrotecan | AZD9592; AZD-9592 | Phase 1 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| ATH-1105 | ATH-1105 | Phase 1 Clinical | Athira Pharma Inc | Amyotrophic Lateral Sclerosis; Frontotemporal Dementia | Details |
| TAVO-412 | TAVO-412 | Phase 1 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd | Neoplasms; Solid tumours | Details |
| NP-107 | NP107; NP-107 | Phase 1 Clinical | Shanghai Nawei Biotechnology Co Ltd | Solid tumours | Details |
| BGC-0902 | BGC-0902; BG-C0902; BGC0902 | Phase 1 Clinical | Brightgene Bio-Medical Technology Co Ltd | Neoplasms; Solid tumours | Details |
| LMV-12(HE003) | LMV-12(HE003) | Phase 1 Clinical | Nanchang Hongyi Technology Co Ltd | Solid tumours | Details |
| GST-HG161 | GST-HG161 | Phase 1 Clinical | Fujian Cosunter Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd | Carcinoma, Hepatocellular; Neoplasms; Solid tumours | Details |
| Metatinib Trometamol | BMS-817378; SIM-817378 | Phase 1 Clinical | Bristol-Myers Squibb Company | Colorectal Neoplasms; Liver Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) | NP-01 | Phase 1 Clinical | Nanjing Nadingfei Pharmaceutical Technology Co Ltd, Shijiazhuang No 4 Pharmaceutical Co Ltd | Liver Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SAIT-301 | SAIT-301 | Phase 1 Clinical | Samsung Medical Center | Neoplasms | Details |
| c-Met targeted radiotheragnostic pair (Edinburgh Molecular Imaging) | Clinical | Edinburgh Molecular Imaging Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Solid tumours | Details | |
| NPS-1034 | HOPE-777; KDDF-201111-02 | Neopharma Ltd | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Envonalkib | TQ-B3139; CT-1139; CT-711 | Approved | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 安洛晴 | Mainland China | Carcinoma, Non-Small-Cell Lung | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2024-06-11 | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | Details |
| Crizotinib | PF-1066; PF-2341066; PF-02341066; PF-002341066 | Approved | Pfizer Inc | 赛可瑞, Xalkori | United States | Carcinoma, Non-Small-Cell Lung | Pf Prism Cv | 2011-08-26 | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Granuloma, Plasma Cell; Hematologic Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Multiple Myeloma; Myofibroma; Neoplasm Metastasis; Neoplasms; Neurilemmoma; Neuroblastoma; Neurofibromatosis 2; Renal Insufficiency; Solid tumours; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Uveal melanoma | Details |
| Unecritinib | TQ-B3101; TTQ-B3101 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Southeast University | 安柏尼 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2024-04-24 | Carcinoma, Non-Small-Cell Lung; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Neoplasms; Stomach Neoplasms | Details |
| Glumetinib | HH-SCC244; SCC244; SCC-244 | Approved | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | 海益坦, Haiyitan | Mainland China | Carcinoma, Non-Small-Cell Lung | ShangHai HaiHe Biopharma Co Ltd | 2023-03-07 | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Tepotinib hydrochloride hydrate | MSC-2156119J; MSC-2156119; EMD-1214063 | Approved | Merck Serono | Tepmetko, テプミトコ, TEPMETKO | Japan | Carcinoma, Non-Small-Cell Lung | Merck KGaA, Darmstadt, Germany | 2020-03-25 | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours | Details |
| Capmatinib Hydrochloride | NVP-INC280-NX; C2A374O70X; INC-280; INCB-028060; INCB-28060 | Approved | Incyte Corp, Novartis Pharma Ag | Tabrecta, 妥瑞达 | United States | Carcinoma, Non-Small-Cell Lung | Novartis Pharmaceuticals Corp | 2020-05-06 | Adenocarcinoma of Lung; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Glioblastoma; Glioma; Gliosarcoma; Hematologic Neoplasms; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroblastoma; Sarcoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Savolitinib | HM-5016504; AZD-6094; HMP-504; HMPL-504 | Approved | 沃瑞沙, ORPATHYS | Mainland China | Carcinoma, Non-Small-Cell Lung | Hutchison Medipharma Ltd | 2021-06-22 | Adenocarcinoma; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Diffuse Intrinsic Pontine Glioma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Glioma; Kidney Diseases; Kidney Neoplasms; Lung Neoplasms; Medulloblastoma; Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Solid tumours; Stomach Neoplasms; Urologic Neoplasms | Details | |
| Ensartinib Hydrochloride | X-396 | Approved | Xcovery | 贝美纳, ENSACOVE | Mainland China | Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2020-11-17 | Brain metastases; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Ependymoma; Glioma; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Lung Neoplasms; Lymphoma, Non-Hodgkin; Medulloblastoma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Wilms Tumor; Xanthogranuloma, Juvenile | Details |
| Amivantamab/Hyaluronidase | Approved | Janssen Biotech Inc | Rybrevant Faspro, 锐珂捷 | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2025-12-17 | Carcinoma, Non-Small-Cell Lung | Details | |
| Amivantamab | JNJ-61186372; JNJ-372; JNJ-6372; CNTO4424; CNTO-4424 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | RYBREVANT | United States | Carcinoma, Non-Small-Cell Lung | Janssen Biotech Inc | 2021-05-21 | Adenocarcinoma; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Lung Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin | Details |
| Telisotuzumab vedotin | ABT-399; ABBV-399 | Approved | Abbvie Inc | EMRELIS | United States | Carcinoma, Non-Small-Cell Lung | Abbvie Inc | 2025-05-14 | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details |
| Vebreltinib | PLB-1001; CBT-101; APL-101; CBI-3103 | Approved | Crown Bioscience(Taicang)Co Ltd | 万比锐 | Mainland China | Carcinoma, Non-Small-Cell Lung | Beijing Purunao Biotechnology Co Ltd | 2023-11-16 | Astrocytoma; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colonic Neoplasms; Ganglioglioma; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Hepatic Insufficiency; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms | Details |
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main